Loading clinical trials...
Loading clinical trials...
Short Course Neoadjuvant Chemo-radiotherapy Plus Anti-PD-1 Antibody (Toripalimab) for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2）
Conditions
Interventions
Neoadjuvant Chemotherapy
Neoadjuvant Toripalimab
+1 more
Locations
1
China
Jiangsu Cancer Hospital /Jiangsu Institute of Cancer Research
Nanjing, Jiangsu, China
Start Date
April 29, 2022
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2024
Last Updated
June 27, 2022
Lead Sponsor
Jiangsu Cancer Institute & Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions